This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Tauchi T, Broxmeyer HE . BCR-ABL signal transduction Int J Hematol 1995 61: 105–112
Sausville EA . A BCR-ABL kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges Nature 1999 91: 102–103
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmerman J, Lydon NB . Effects of a selective inhibitor of the abl tyrosine kinase on the growth of BCR-ABL positive cells Nat Med 1996 2: 561–566
le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F, Gambacorti-Passerini C . In vivo eradication of human BCR-ABL-positive leukemia cells with an ABL kinase inhibitor J Natl Cancer Inst 1999 91: 163–168
Topaly J, Zeller WJ, Fruehauf S . Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells Leukemia 2001 (in press)
Hehlmann R . Trial of IFN or STI571 before proceeding to allografting for CML? Leukemia 2000 14: 1560–1562
Nishimaki J, Miyazawa M, Yaguchi M, Katagiri T, Kawanishi Y, Toyama K, Ohyashiki K, Hashimoto S, Nakaya K, Takiguchi T . Vitamin K2 induces apotosis of a novel cell line established from a patient with myelodysplastic syndrome in blastic transformation Leukemia 1999 13: 1399–1405
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nakajima, A., Tauchi, T. & Ohyashiki, K. ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis. Leukemia 15, 989–990 (2001). https://doi.org/10.1038/sj.leu.2402137
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402137
This article is cited by
-
An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259
Oncogene (2008)
-
Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia
Oncogene (2006)
-
Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways
Oncogene (2003)
-
Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy
Leukemia (2003)
-
Telomeres and telomerase in hematologic neoplasia
Oncogene (2002)